Search Results - "McShane, L."

REporting recommendations for tumour MARKer prognostic studies (REMARK) by MCSHANE, L. M, ALTMAN, D. G, SAUERBREI, W, TAUBE, S. E, GION, M, CLARK, G. M

“…Despite years of research and hundreds of reports on tumour markers in oncology, the number of markers that have emerged as clinically useful is pitifully…”
Get full text

51 Statistical Challenges in the Development of Reliable and Clinically Meaningful Biomarkers by McShane, L

Get full text

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q by Jhaveri, K.L., Wang, X.V., Makker, V., Luoh, S.-W., Mitchell, E.P., Zwiebel, J.A., Sharon, E., Gray, R.J., Li, S., McShane, L.M., Rubinstein, L.V., Patton, D., Williams, P.M., Hamilton, S.R., Conley, B.A., Arteaga, C.L., Harris, L.N., O’Dwyer, P.J., Chen, A.P., Flaherty, K.T.

“…The National Cancer Institute—Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic…”
Get full text

In Pursuit of Greater Reproducibility and Credibility of Early Clinical Biomarker Research by McShane, LM

“…A major difference between preclinical drug development studies and early clinical biomarker development studies is that the latter are often conducted…”
Get full text

Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group by Dowsett, Mitch, Nielsen, Torsten O., A'Hern, Roger, Bartlett, John, Coombes, R. Charles, Cuzick, Jack, Ellis, Matthew, Henry, N. Lynn, Hugh, Judith C., Lively, Tracy, McShane, Lisa, Paik, Soon, Penault-Llorca, Frederique, Prudkin, Ljudmila, Regan, Meredith, Salter, Janine, Sotiriou, Christos, Smith, Ian E., Viale, Giuseppe, Zujewski, Jo Anne, Hayes, Daniel F.

“…Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical assessment of the proportion of cells staining for the nuclear…”
Get full text

Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer by Korn, E.L., Sachs, M.C., McShane, L.M.

“…A trial-level surrogate end point for a randomized clinical trial may allow assessment of the relative benefits of the treatment to be performed at an earlier…”
Get full text

Pitfalls in the Use of DNA Microarray Data for Diagnostic and Prognostic Classification by Simon, Richard, Radmacher, Michael D., Dobbin, Kevin, McShane, Lisa M.

“…Many studies profiling gene expression in human cancers have been completed and are in progress. Some studies (19-22) attempt to build predictors of patient…”
Get full text

Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer by Bodelon, C., Polley, M.Y., Kemp, T.J., Pesatori, A.C., McShane, L.M., Caporaso, N.E., Hildesheim, A., Pinto, L.A., Landi, M.T.

“…Some patients diagnosed with early-stage lung cancer and treated according to standard care survive for only a short period of time, while others survive for…”
Get full text

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial by Mansfield, A. S., Wei, Z., Mehra, R., Shaw, A. T., Lieu, C. H., Forde, P. M., Drilon, A. E., Mitchell, E. P., Wright, J. J., Takebe, N., Sharon, E., Hovelson, D., Tomlins, S., Zeng, J., Poorman, K., Malik, N., Gray, R. J., Li, S., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P. M., Hamilton, S. R., Conley, B. A., Arteaga, C. L., Harris, L. N., O’Dwyer, P. J., Chen, A. P., Flaherty, K. T.

“…The NCI-MATCH was designed to characterize the efficacy of targeted therapies in histology-agnostic driver mutation-positive malignancies. Sub-protocols F and…”
Get full text

Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans by Brown, P., Cervenáková, L., McShane, L.M., Barber, P., Rubenstein, R., Drohan, W.N.

“…BACKGROUND: Solid evidence from experimentally infected animals and fragmentary evidence from naturally infected humans indicate that blood may contain low…”
Get full text

Glucagon receptor antagonist and GIP agonist combination for diet-induced obese mice by McShane, L M, Irwin, N, O’Flynn, D, Franklin, Z J, Hewage, C M, O’Harte, F P M

“…Ablation of glucagon receptor signaling represents a potential treatment option for type 2 diabetes (T2DM). Additionally, activation of glucose-dependent…”
Get full text

Inherited polymorphisms in the RNA-mediated interference machinery affect microRNA expression and lung cancer survival by Rotunno, M, Zhao, Y, Bergen, A W, Koshiol, J, Burdette, L, Rubagotti, M, Linnoila, R I, Marincola, F M, Bertazzi, P A, Pesatori, A C, Caporaso, N E, McShane, L M, Wang, E, Landi, M T

“…Background: MicroRNAs (miRs) have an important role in lung carcinogenesis and progression. Single-nucleotide polymorphisms (SNPs) in genes involved in miR…”
Get full text

NCI-MATCH Arms N & P: Phase II study of PI3K beta inhibitor GSK2636771 in patients (pts) with cancers (ca) with PTEN mutation/deletion (mut/del) or PTEN protein loss by Janku, F, Jegede, O, Puhalla, S L, Konstantinopoulos, P, Meric-Bernstam, F, Mitchell, E P, Zwiebel, J A, McShane, L M, Li, S, Rubinstein, L V, Doyle, L A, Patton, D, Conley, B A, O'Dwyer, P J, Harris, L N, Arteaga, C, Williams, P M, Hamilton, S R, Chen, A P, Flaherty, K T

Get full text

Epstein-Barr virus microRNAs and lung cancer by Koshiol, J, Gulley, M L, Zhao, Y, Rubagotti, M, Marincola, F M, Rotunno, M, Tang, W, Bergen, A W, Bertazzi, P A, Roy, D, Pesatori, A C, Linnoila, I, Dittmer, D, Goldstein, A M, Caporaso, N E, McShane, L M, Wang, E, Landi, M T

“…Background: We conducted the first analysis of viral microRNAs (miRNAs) in lung cancer, with a focus on Epstein–Barr virus (EBV). Methods: We evaluated viral…”
Get full text

Iatrogenic Creutzfeldt-Jakob disease at the millennium by BROWN, P, PREECE, M, D'AIGNAUX, J. H, CERVENAKOVA, L, FRADKIN, J, SCHONBERGER, L. B, COLLINS, S. J, BRANDEL, J.-P, SATO, T, MCSHANE, L, ZERR, I, FLETCHER, A, WILL, R. G, POCCHIARI, M, CASHMAN, N. R

“…The causes and geographic distribution of 267 cases of iatrogenic Creutzfeldt-Jakob disease (CJD) are here updated at the millennium. Small numbers of…”
Get full text

NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership by Chen, A, Conley, B, Hamilton, S, Williams, M, O'Dwyer, P, Arteaga, C, Gray, R, McShane, L, Li, S, Rubinstein, L, Patton, D, Sazali, K, Zwiebel, J, Mitchell, E, Smith, M.L, Dragaud, D, Little, R, Comis, R, Abrams, J, Flaherty, K

“…Background: The NCI MATCH is an efficacy signal-finding trial to identify molecular alterations that can be matched to targeted treatments in tumor biopsies…”
Get full text

Breast Cancer Classification and Prognosis Based on Gene Expression Profiles from a Population-Based Study by Sotiriou, Christos, Neo, Soek-Ying, McShane, Lisa M., Korn, Edward L., Long, Philip M., Jazaeri, Amir, Martiat, Philippe, Fox, Steve B., Harris, Adrian L., Liu, Edison T.

“…Comprehensive gene expression patterns generated from cDNA microarrays were correlated with detailed clinico-pathological characteristics and clinical outcome…”
Get full text

Synthesis, kinetic evaluation, and utilization of a biotinylated dipeptide proline diphenyl phosphonate for the disclosure of dipeptidyl peptidase IV-like serine proteases by Gilmore, Brendan F., Carson, Louise, McShane, Laura L., Quinn, Derek, Coulter, Wilson A., Walker, Brian

“…In this study, we report on the synthesis, kinetic characterisation, and application of a novel biotinylated and active site-directed inactivator of dipeptidyl…”
Get full text

Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data by McShane, Lisa M., Radmacher, Michael D., Freidlin, Boris, Yu, Ren, Li, Ming-Chung, Simon, Richard

“…Motivation: Recent technological advances such as cDNA microarray technology have made it possible to simultaneously interrogate thousands of genes in a…”
Get full text

Reporting recommendations for tumor marker prognostic studies (remark) by McShane, L M, Altman, D G, Sauerbrei, W, Taube, S E, Gion, M, Clark, G M

“…Despite years of research and hundreds of reports on tumor markers in oncology, the number of markers that have emerged as clinically useful is pitifully…”
Get more information